FGFR3

Daily injection speeds growth in children with hypochondroplasia

In the phase 3 CANOPY-HCH-3 trial, vosoritide added 2.33 cm a year to growth against placebo, and BioMarin has now asked the FDA to approve it.

9 September 2026